Tenax Therapeutics, Inc. (TENX) Earnings History
Annual and quarterly earnings data from 1996 to 2024
Loading earnings history...
TENX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TENX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export TENX earnings history in CSV or JSON format
Free sign-in required to download data
Tenax Therapeutics, Inc. (TENX) Earnings Overview
As of May 8, 2026, Tenax Therapeutics, Inc. (TENX) reported trailing twelve-month net income of -$43M, reflecting +96.3% year-over-year growth. The company earned $-1.09 per diluted share over the past four quarters.
Looking at the long-term picture, TENX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$800,000 in fiscal 1998.
Tenax Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ATHA (-$129M net income), NKTR (-$164M net income, -297.1% margin), ACAD ($376M net income, 36.5% margin), TENX has comparable earnings metrics. Compare TENX vs ATHA →
TENX Earnings vs Peers
Earnings metrics vs comparable public companies
TENX Historical Earnings Data (1996–2024)
29 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$18M | -128.3% | -$19M | $-1.15 | - | - |
| 2023 | -$8M | +30.2% | -$8M | $-31.04 | - | - |
| 2022 | -$11M | +66.0% | -$11M | $-600.80 | - | - |
| 2021 | -$32M | -229.6% | -$33M | $-2524.80 | - | - |
| 2020 | -$10M | -17.4% | -$10M | $-2125.38 | - | - |
| 2019 | -$8M | -23.2% | -$9M | $-26.60 | - | - |
| 2018 | -$7M | +22.9% | -$7M | $-7359.14 | - | - |
| 2017 | -$9M | +79.9% | -$9M | $-10022.32 | - | - |
| 2016 | -$44M | -211.9% | -$53M | $-624.82 | - | - |
| 2015 | -$14M | +0.0% | -$16M | $-200.61 | -28571.6% | -31729.6% |
See TENX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TENX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TENX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTENX — Frequently Asked Questions
Quick answers to the most common questions about buying TENX stock.
Is TENX growing earnings?
TENX EPS is $-1.09, with earnings growth accelerating to +96.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-43M.
What are TENX's profit margins?
Tenax Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are TENX's earnings?
TENX earnings data spans 1996-2024. The accelerating earnings trend is +96.3% YoY. Historical data enables comparison across business cycles.